At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
MP1032 +1 moredrug
Likely dose
MP1032 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Trial of Two Oral Doses (150 mg Bid / 300 mg Bid) of MP1032 in Male and Female Patients With Moderate-to-Severe Chronic Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating MP1032 and Placebo for Psoriasis. Completed, enrolled 155 participants across 19 sites in 2 countries.
Detailed Summary
The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany, Poland
CollaboratorsBioskin GmbH
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedOct 2018
Primary CompletionJun 2019
TodayJul 2026
First PostedOct 15, 2018
Enrollment StartFeb 27, 2018
Primary CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.7 years ago
Interventions
MP1032drug
hard gelatin capsules containing 50mg MP1032 as active ingredient
Placebodrug
hard gelatin capsules containing no active ingredient